RT Journal Article
T1 Real-life effect of a microcrystalline tyrosine adjuvanted mite immunotherapy in patients with allergic rhinitis.
A1 Roger, Albert
A1 Malet, Alfons
A1 Moreno, Victoria
A1 Parra, Antonio
A1 Gutiérrez, Diego
A1 Lleonart, Ramón
A1 Moreno, Francisco
A1 Valero, Antonio
A1 Navarro, Begoña
A1 Hinojosa, Belén
A1 Justicia, José L
K1 Dermatophagoides pteronyssinus
K1 adjuvants
K1 allergic rhinitis
K1 effectiveness
K1 house dust mites
K1 real-life clinical practice
K1 safety
K1 subcutaneous allergen immunotherapy
AB Aim: Evaluate the effectiveness and safety of immunotherapy with Acarovac Plus® in a 1-year prospective multicentered real-life study. Methods: A total of 118 adults with allergic rhinitis sensitized to Dermatophagoides received subcutaneous immunotherapy with Acarovac Plus. Treatment outcomes were evaluated at baseline, 6 months and 1 year after treatment initiation. Primary end point was the evolution of the combined symptom and medication score. Secondary end points included other effectiveness outcomes and measurement of product tolerability. Results: Acarovac Plus induced significant improvements in primary and secondary end points after 6 months compared with baseline. These differences persisted after 1 year of treatment (p
YR 2020
FD 2020-01-08
LK http://hdl.handle.net/10668/14927
UL http://hdl.handle.net/10668/14927
LA en
DS RISalud
RD Apr 10, 2025